Table 4.
Multivariate Cox regression analysis of renal progression with the estimated contribution of each covariates to the prediction
|
HR |
p |
R2 reduction |
|
|---|---|---|---|
| (95% CI) | (%) | ||
|
eGFR ≥ 45 ml/min/1.73 m2 |
|
|
|
| Diabetes (yes vs. no) |
1.91 (1.18 - 2.11) |
0.035 |
1.11 |
| Hypoalbuminemia (yes vs. no) |
3.25 (1.73 - 4.61) |
<0.001 |
6.91 |
| CVD (yes vs. no) |
2.81 (2.61 - 4.82) |
0.004 |
2.39 |
|
eGFR < 45 ml/min/1.73 m2 |
|
|
|
|
Model 1 |
|
|
|
| Age |
0.98 (0.97 - 0.99) |
<0.001 |
0.70 |
| Gender (male vs. female) |
0.93 (0.74 - 1.18) |
0.059 |
0.10 |
| Diabetes (yes vs. no) |
1.71 (1.42 - 2.34) |
<0.001 |
1.29 |
| CKD stage |
2.67 (2.19 - 3.26) |
<0.001 |
7.67 |
| Metabolic complications (≥3 vs. <3) |
2.18 (1.48 - 3.22) |
<0.001 |
0.51 |
|
Model 2 |
|
|
|
| Age |
0.98 (0.97 - 0.99) |
<0.001 |
0.74 |
| Gender (male vs. female) |
1.05 (0.81 - 1.37) |
0.704 |
<0.001 |
| CKD stage |
2.30 (1.87 - 2.83) |
<0.001 |
5.68 |
| CVD (yes vs. no) |
3.29 (1.56 - 6.99) |
0.002 |
0.29 |
| Hyperphosphatemia (yes vs. no) |
2.09 (1.57 - 2.80) |
<0.001 |
1.26 |
| Hyperparathyroidism (yes vs. no) |
0.92 (0.64- 1.31) |
0.633 |
<0.001 |
| Anemia (yes vs. no) |
2.64 (1.38 - 5.01) |
0.003 |
0.41 |
| Hyperuricemia (yes vs. no) |
1.03 (0.78 - 1.35) |
0.857 |
<0.001 |
| Hypoalbuminemia (yes vs. no) |
2.58 (2.04 - 3.57) |
<0.001 |
4.54 |
| Acidosis (yes vs. no) |
1.24 (0.93 - 1.67) |
0.15 |
<0.001 |
| Microinflammation (yes vs. no) | 1.36 (1.02 - 1.80) | 0.038 | 0.15 |
HR, hazard ratios; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease.
Model 1: adjusted for patient demographic characteristics, CKD stage and number of complications.
Model 2: hierarchical analyses of diverse metabolic complications adjusted for age, gender and CKD stage.